Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

Phase 3bexicaserinPositive

AI Analysis

Summary

Lundbeck announced completion of patient randomization in DEEp SEA, a global Phase III trial evaluating bexicaserin in children and adults with Dravet syndrome. This represents an important milestone in the Phase III DEEp program.

Clinical Trial Data

Phase

Phase III

Outcome Details

Last patient randomized in DEEp SEA trial

Importance:5/10

Sentiment:

0.30

Phase 3Dravet syndromeDEEp SEA trialClinical milestone

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Pharma on September 15, 2026 7:32 AM

Read Original